Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain TXMD message board posts where the ticker symbol TXMD has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest TXMD SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001387131-18-006314 Size: 16 KB
2018-11-16
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001387131-18-006220 Size: 15 KB
2018-11-14
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001387131-18-006131 Size: 17 KB
2018-11-13
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001387131-18-006074 Size: 8 KB
2018-11-13
8-K  Documents Current report, items 7.01 and 9.01
Acc-no: 0001387131-18-006073 (34 Act)  Size: 32 MB
2018-11-13 001-00100
181174960
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001387131-18-005976 (34 Act)  Size: 4 MB
2018-11-08 001-00100
181168111
8-K  Documents Current report, items 2.02, 7.01, and 9.01
Acc-no: 0001387131-18-005954 (34 Act)  Size: 8 MB
2018-11-07 001-00100
181166373
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001387131-18-005729 Size: 15 KB
2018-10-29
8-K  Documents Current report, items 7.01 and 9.01
Acc-no: 0001387131-18-005702 (34 Act)  Size: 4 MB
2018-10-29 001-00100
181142703
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001387131-18-005637 Size: 16 KB
2018-10-25
More TXMD SEC Filings


Related news from
Mon, 19 Nov 2018
18:00:44 +0000
Fast-growing pharmaceutical company signs $20M lease to expand Boca Raton HQ
TherapeuticsMD signed a 56,212-square-foot lease to replace its headquarters to a larger building in Boca Raton. The pharmaceutical company (Nasdaq: TXMD) will move into 951 Yamato Road. Jay M. Grossman and Richard W. Brockney of NAI/Merin Hunter Codman represented landlord Brookwood Financial Partners in the deal.
Mon, 12 Nov 2018
21:30:00 +0000
TherapeuticsMD Announces Participation in Three Upcoming Investor Conferences
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the company will participate in three upcoming healthcare investor conferences. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conferences.
Thu, 08 Nov 2018
08:53:28 +0000
Edited Transcript of TXMD earnings conference call or presentation 7-Nov-18 9:30pm GMT
Q3 2018 TherapeuticsMD Inc Earnings Call
Wed, 07 Nov 2018
23:12:37 +0000
TherapeuticsMD: 3Q Earnings Snapshot
The Boca Raton, Florida-based company said it had a loss of 16 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Wed, 07 Nov 2018
21:05:00 +0000
TherapeuticsMD Announces Third Quarter 2018 Financial Results
-Strong early launch indicators for IMVEXXY™-
Tue, 06 Nov 2018
18:12:26 +0000
TherapeuticsMD Inc’s (NASDAQ:TXMD) Profit Outlook
TherapeuticsMD Inc’s (NASDAQ:TXMD): TherapeuticsMD, Inc. operates as a women’s health care product company. With the latest financial year loss of -US$77m and a trailing-twelve month of -US$94m, the US$1.2b market-cap<div><a class="permalink" href="https://simplywall.st/news/yahoo-post/therapeuticsmd-incs-nasdaqtxmd-profit-outlook/">Read More...</a></div>
Tue, 30 Oct 2018
11:00:00 +0000
TherapeuticsMD to Report Third Quarter 2018 Financial Results on November 7, 2018
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018, after the closing of the U.S. financial markets.
Mon, 29 Oct 2018
19:04:00 +0000
Why TherapeuticsMD Is Sinking Despite Sharing Good News
An FDA approval usually triggers a rally, so why are shares down today?
Mon, 29 Oct 2018
14:31:02 +0000
TherapeuticsMD (TXMD) Q3 Earnings Preview: What to Watch Ahead of the Release
TherapeuticsMD (TXMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mon, 29 Oct 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: TherapeuticsMD and Horizon Pharma Public
NEW YORK, NY / ACCESSWIRE / October 29, 2018 / U.S. equities rolled back on Friday as disappointing corporate earnings added to the bearish sentiment in the market. The Dow Jones Industrial Average shed ...
Mon, 29 Oct 2018
10:27:37 +0000
U.S. FDA approves TherapeuticsMD's menopause drug
The U.S. Food and Drug Administration (FDA) approved TherapeuticsMD's oral hormone therapy for menopause symptoms such as hot flashes, sleep disturbances and night sweats, the company said on Monday. The regulatory nod is the third in five months for the drugmaker, which received approvals for a birth control device and another hormone therapy for menopause symptoms. The therapy, Bijuva, is an oral softgel capsule containing a combination of artificial hormones chemically identical to human female sex hormones estradiol and progesterone.
Mon, 29 Oct 2018
10:00:00 +0000
TherapeuticsMD Announces FDA Approval of TX-001HR: BIJUVA™ (Estradiol and Progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved BIJUVA™ (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical* hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.
Thu, 25 Oct 2018
12:02:20 +0000
See what the IHS Markit Score report has to say about TherapeuticsMD Inc.
Short interest is extremely high for TXMD with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TXMD. Over the last one-month, outflows of investor capital in ETFs holding TXMD totaled $431 million.
Wed, 24 Oct 2018
12:25:00 +0000
Consolidated Research: 2018 Summary Expectations for Novavax, Caesars Entertainment, SeaWorld Entertainment, LendingTree, CVS Health, and TherapeuticsMD — Fundamental Analysis, Key Performance Indications
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Tue, 16 Oct 2018
10:33:00 +0000
3 Biotechs Awaiting FDA Approval Decisions
With new drug applications under review at the moment, these 3 biotech stocks could surge in the weeks ahead.
Thu, 11 Oct 2018
14:30:00 +0000
Cannabis and Biotech Stocks That Have Run Parabolically
HENDERSON, NV / ACCESSWIRE / October 11, 2018 / Cannabis and Biotech companies have been receiving increased attention from the street as of late. One particular company that has caught significant attention ...
Fri, 28 Sep 2018
12:32:00 +0000
Today's Research Reports on Trending Tickers: TherapeuticsMD and Endo International
NEW YORK, NY / ACCESSWIRE / September 28, 2018 / U.S. markets finished higher on Thursday as the jobless claims increase was smaller than expected and second quarter GDP rose 3.1%, marking the best growth ...
Fri, 28 Sep 2018
11:00:00 +0000
TherapeuticsMD Announces Multiple Presentations Related to Imvexxy™ and TX-001HR at the 2018 Annual Meeting of the North American Menopause Society
TherapeuticsMD, Inc. , an innovative women’s healthcare company, today announced the schedule of ten oral presentations and posters at NAMS 2018, the annual meeting of the North American Menopause Society being held in San Diego, California on October 3-6, 2018, related to ImvexxyTM and TX-001HR, the Company’s investigational bio-identical hormone therapy combination of estradiol and progesterone in ...
Thu, 27 Sep 2018
20:05:00 +0000
TherapeuticsMD Enters Into Label Discussions for TX-001HR
TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the Company has entered into discussions with the U.S. Food and Drug Administration (FDA) regarding the proposed label for TX-001HR, the Company’s investigational bio-identical hormone therapy combination of estradiol and progesterone in a single, oral softgel for the treatment of moderate-to-severe vasomotor symptoms due to menopause. As previously announced, the Prescription Drug User Fee Act (PDUFA) target action date for the completion of the FDA’s review of the new drug application (NDA) for TX-001HR is October 28, 2018. The Company does not anticipate providing subsequent updates with respect to label discussions prior to the PDUFA target action date.
Wed, 26 Sep 2018
12:30:12 +0000
Implied Volatility Surging for TherapeuticsMD (TXMD) Stock Options
Investors need to pay close attention to TherapeuticsMD (TXMD) stock based on the movements in the options market lately.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has meant the difference between mediocre and stellar stock performance, peace of mind about retirement and meeting and making wonderful friends. VF is simply the BEST." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards